TARRYTOWN, N.Y., Sept. 23, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced today that effective September 23, 2013 the Company's symbol for its common stock trading on the OTCQX trading platform will change to "IMNP". The Company's common stock had been required to trade under the symbol "EPCTD" since August 21, 2013 as a result of the previously implemented 1-for-40 reverse stock split. The Company's common stock has been trading on the NASDAQ OMX Stockholm Exchange under the symbol "IMNP" since August 21, 2013, so as a result of this most recent change the Company's common stock will be trading under the same symbol in all of its trading markets. Dr. Daniel G. Teper, the Company's Chairman and Chief Executive Officer, commented, "This change now aligns Immune's trading symbol on the OTCQX with our symbol on the NASDAQ OMX Stockholm Exchange, enabling our investors to easily identify the Company and track our progress as we achieve new clinical and business development milestones." On August 26, 2013, Immune Pharmaceuticals announced the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation, forming a company focused on the development of antibody therapeutics, including bertilimumab, which is in Phase II clinical development for ulcerative colitis and bullous pemphigoid, an orphan auto-immune indication, and NanomAbs®, a platform of antibody targeted nanoparticles for cancer treatment. About Immune Pharmaceuticals Inc. Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP; OTCQX: IMNP, formerly EPCTD) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn's disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company's growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.